Keywords pandemic - COVID-19 - cancer surgery - outcomes - complication rates
Introduction
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as
pandemic on March 11, 2020.[1 ] In India, the first case was reported on January 30, 2020.[2 ] Since then there has been an exponential rise in the number of infected patients,
crossing half a million by June end. At the onset of this pandemic, there was a national
lockdown of 77 days starting on March 23. This resulted in complete paralysis of transport
and all nonessential services. The Indian government has adapted the multiprong strategy
to control the community spread of the virus. However, treatment of non-COVID-19 communicable
and noncommunicable diseases took a backseat. The WHO estimates interruption in vaccination
of 80 million infants due to this pandemic with Michigan study noting a significant
decline in the vaccination drive in all the age groups of infants.[3 ] According to the survey done among world emergency services members, there has been
an 81.8% decrease in the total number of patients undergoing emergency surgery and
56.1% of the collaborators observed more severe septic abdominal diseases during the
pandemic, especially for perforated appendicitis and cholecystitis (41.8 and 40.2%,
respectively) due to delay in diagnosis and intervention.[4 ]
Fear of acquiring the COVID-19 infection in hospital settings restricted patients
to reaching health-care facilities. There was also an intense fear factor among health-care
personnel regarding the risks involved in dealing with possible COVID-19 patients;
these fears included high postoperative complication and mortality rates in COVID-19-positive
patients, fear of acquiring infection, and bringing the infection home. Other countries
where the infection was rampant were reporting higher mortality in general, and health-care
personnel were getting infected leading to severe illness and at times death.[5 ] All these factors led to a significant decrease in the number of patients being
operated for cancer.[6 ] Thus, we decided to conduct a multicentric observational study to look at the outcomes
of surgeries during this period. Our primary aim was to identify if there was any
difference in the complication rates as well as mortality rates for the cancer patients
operated during the pandemic. We also aimed to find out the infection rates of the
health-care personnel involved in the care of these patients right from admission
to discharge. These personnel included doctors, nurses, paramedical and other ancillary
hospital staff involved in the care of these patients.
Materials and Methods
This was a retrospective study of prospectively maintained database of the five tertiary
care centers (four centers of surgical oncology and a center of gynae-oncology) located
in different parts of India: Mumbai, Bangalore, Gurugram, and Mohali. All patients
(148 cancer patients) who underwent surgery for oncological indication from March
23, 2020 to May 22, 2020 were included in group A as study group. For the purpose
of comparison, data of the patients (168 cancer patients) who underwent surgery indicated
for cancer from January 1 to January 31, 2020 were included in group B. Thus, group
A consisted of patients operated during COVID-19 pandemic and group B consisted of
cancer patients operated during non-COVID-19 period. In total, 316 patients were included
in the study. This group represented the control group as all these surgeries were
done before the outbreak of COVID-19 pandemic in India.
All the adult patients above the age of 18, histopathologically proven cancer, indicated
for surgery were included in the study. Patients with incomplete data including 11
patients from group A and 19 patients from Group B were excluded.
In the study group (group A), there were two subsets of patients; the first subset
had no patients tested preoperatively for COVID-19 infection (from March 23, 2020
to April 15, 2020) and the second included patients who had been tested for COVID-19
infection. However, it varied according to the centers ([Table 1 ]). For the second subset, all the patients (11 patients) who were tested positive
(reverse transcriptase–polymerase chain reaction [RT-PCR] positive) were not included
in the study. All surgeries in group A, that is, the study group, were performed with
all precautions including complete personal protective equipment’s protocol. Data
were manually collected from the electronic database and from the patients files extracted
from the medical record department.
Table 1
Details of different centers of hospitals across India
Centers
Group A
Group B
COVID-19 test commencing date
Number of COVID-19 patients in the state
Abbreviation: COVID-19, coronavirus disease 2019.
Mumbai
61
57
April 15
30,512
Bangalore
22
45
April 20
18,016
Mohali
47
34
April 20
114
Gurugram
9
20
April 20
5,463
Gurugram
(Gynae)
9
12
April 20
5,463
Preoperative parameters gathered and recorded included gender, age, Eastern Cooperative
Oncology Group (ECOG), grade of surgery, comorbidities, chest X-ray, COVID-19 testing
status, and primary site of cancer. Grade of surgery was categorized into four levels
according to the complexity and technical difficulty of the surgery as defined by
Lei et al.[11 ] Intraoperatively parameters assessed included duration of surgery, blood loss, intraoperative
injury if any, and type of anesthesia. Postoperative parameters including infection
rate, change in antibiotics, prolonged antibiotics, and complication rates (Clavien-Dindo
[CD] classification)[7 ] were documented. Any symptoms similar to COVID-19 clinical presentation including
fever, sore throat, fatigue, loss of taste or smell, nasal congestion, headache, muscle
or joint pain, skin rash, nausea or vomiting, diarrhea, chills, or dizziness were
also documented on subsequent follow-up to 15 days postoperatively. Laboratory confirmation
of COVID-19 was done by quantitative RT-PCR on samples from the respiratory tract
for all patients preoperatively in second subset of group A and for all symptomatic
postoperative patients. Postoperative surgical outcomes were the primary end-point,
while change in the intraoperative parameters was secondary outcome.
Data Accessibility Statement
Data will be made available as per request.
Statistical Analysis
Demographic data were summarized with descriptive statistics. Continuous data was
represented as mean (standard deviation) or median (interquartile range [IQR]) and
categorical data was reported in counts (percentage). The Shapiro-Wilk test was used
to check the normality of each variable. Descriptive analysis was performed to identify
the distribution of variables under study. Comparison between the two groups with
categorical demographic and clinicodemographic variables including gender, grade of
surgery, primary site, intraoperative event, postoperative intensive care unit (ICU)
stay, site of infection, complication rates, and culture was done using chi-squared
test with Pearson’s test. Mann–Whitney nonparametric test was used for comparison
of continuous demographic and clinicodemographic variables including age, duration
of surgery, blood loss, and hospital stay. For all tests, p -values were two-sided, and a p -value lower than 0.05 was considered statistically significant. Statistical analyses
were performed using SPSS software (released 2017; IBM SPSS Statistics for Windows,
Version 25.0. Armonk, NY: IBM Corp).
Ethics
The study protocol was presented and approved by Fortis institutional ethics committee
(IEC) on June 7, 2020 and waiver of informed consent was obtained (IEC/2020/OAS/04).
The procedures followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional) and with the Helsinki Declaration
of 1964, as revised in 2013.
Results
One-hundred sixty-eight cancer surgeries were performed in group B as compared with
148 patients who underwent oncosurgeries in group A ([Table 2 ]). Sixty-two percent lesser cancer surgeries were performed in the COVID-19 period
as compared with the specific pre-COVID-19 period ([Fig. 1 ]). The median age of the patients in group A was 55.5 years (IQR: 42.25–64.00), while
that of group B control group was 57 years (IQR: 47–65). There was no significant
difference in the median age of the patients operated between the groups (p = 0.173). Group B (44.6%) had more patients above the age of 60 years as compared
with group A (37.2%); however, it did not achieve statistical significance (p = 0.178). Females were in majority in both the time periods (group A vs. group B;
66.9 vs. 67.3%; p = 0.944). Grade of surgery was classified into four categories. Both the groups (group
A and group B) had a similar percentage of the grade of surgeries (p = 0.282) ([Table 2 ]). There was no significant difference in the percentage and type of comorbidities
in both the groups (0.832). Major site of cancer surgeries was similar in both the
groups. Breast cancer surgery (28.5%) was the most common followed by gastrointestinal
surgeries (22.2%), head and neck surgeries (18.4%), gynae-oncology (13.3%), uro-oncology,
and chemoport insertion procedures. There were significantly lower cancer surgeries
in group A for all anatomical sites ([Fig. 2 ]).
Table 2
Comparison of demographics and outcomes (intraoperative and postoperative) between
two time periods
Clinical characteristics
Before COVID-19, n (%)
During COVID-19, n (%)
p -Value
Abbreviations: CD, Clavien-Dindo classification used for complication rates; COVID-19,
coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range.
Gender
Female
113 (67.3%)
99 (66.9%)
0.944
Male
55 (32.7%)
49 (33.1%)
Grade of surgery
Grade 1
48 (28.6%)
36 (24.3%)
0.198
Grade 2
38 (22.6%)
34 (23%)
Grade 3
55 (32.7%)
63 (42.6%)
Grade 4
27 (16.1%)
15 (10.1%)
Comorbidity
No
78 (46.4%)
69 (46.6%)
0.854
One comorbidity
52 (31%)
49 (33.1%)
More than 2 comorbidities
38 (22.6%)
30 (20.3%)
Primary site
Head and neck
34 (20.2%)
24 (16.2%)
0.023
Breast
47 (28%)
43 (29.1%)
Gastrointestinal
42 (25%)
28 (18.9%)
Gynae-oncology
19 (11.3%)
23 (15.5%)
Others
9 (5.4%)
7 (4.7%)
Uro and nephro-oncology
2 (1.2%)
6 (4.1%)
Chemoport procedures
15 (8.9%)
17 (11.5%)
Intraoperative events
Yes
2 (1.2%)
4 (2.7%)
0.326
No
166 (98.8%)
144 (97.3%)
Surgery
OPEN
92.6%
7.4%
<0.0001
Minimal invasive
77.4%
22.6%
Postoperative ICU stay
Yes
11 (6.5%)
13 (8.8%)
0.453
No
157 (93.5%)
135 (91.2%)
Surgical site infection
Yes
13 (7.7%)
10 (6.8%)
0.738
No
155 (92.3%)
138 (93.2%)
Change of antibiotics
Yes
17 (10.1%)
10 (6.8%)
0.286
No
151 (89.9%)
138 (93.2%)
Complication
CD1
3 (1.8%)
9 (6.1%)
0.038
CD2
20 (11.9%)
31 (20.9%)
CD3A
2 (1.2%)
0 (0%)
CD3B
1 (0.6%)
2 (1.4%)
None
141(83.9%)
105(70.9%)
CD4
1(0.6%)
1(0.7%)
Culture
Growth
8(4.8%)
4(2.7%)
0.390
No growth
160(95.2%)
144(97.3%)
Before COVID-19
Median (IQR)
During COVID-19
Median (IQR)
Age (years), median (IQR)
57 (47–65)
55.50(42.25–64)
0.173
Duration of surgery(minutes), median (IQR)
120(60–227.50)
90(48.75–180)
0.023
Blood loss(mL), median(IQR)
30(10–100)
30(15–100)
0.706
Hospital stay(d), median(IQR)
3.00(2.00–6.00)
4(2–5)
0.815
Fig. 1 Comparison of number of cancer patients operated in first 4 weeks between two time
periods (group A vs. group B).
Fig. 2 Comparison of site-specific surgeries in coronavirus disease 2019 (COVID-19) versus
non-COVID pandemic. GI, gastrointestinal.
Majority of patients in both groups had normal chest X-ray findings (97.3 vs. 96.4%).
Four patients had an abnormal chest X-ray in group A. Three of them did not have any
postoperative complication, while one patient had CD-2 type complication. However,
all patients (five) in group B had no postoperative complications. There was no change
in intraoperative events among both the groups. (p = 0.285). Minimally invasive procedures (including laparoscopic surgeries and robotic
surgeries) were performed significantly less in COVID-19 period as compared with pre-COVID-19
period (7.4 vs. 22.6%). The median duration of the operative procedures was significantly
less in group A as compared with group B (90.00 min [IQR: 48.75–180.00 min] vs. 120.00
min [IQR: 60.00–227.50 min]; p = 0.023). There was no significant difference in blood loss among the two study groups
(30.00 mL [IQR: 15.00–100.00 mL] vs. 30.00 mL [IQR: 10.00–100.00 mL]; p = 0.706).
The median length of hospital stay was similar in both the study groups (group A vs.
group B; 4.00 days [IQR: 2.00–5.00] vs. 3.00 days [IQR: 2.00–6.00]; p = 0.815). Postoperative ICU stay (8.8 vs. 6.5%; p = 0.453), postoperatively infection rate (6.8 vs. 7.7%; p = 0.526), and rate of change of antibiotics (6.8 vs. 10.1%; p = 0.319) were similar in both the groups. However, there was significant difference
in CD-2 complication rates (20.3 vs. 11.9%; [Fig. 3 ]). There was no difference in the presence of bacterial or fungal infection in postoperative
blood culture investigation among the study groups (2.7 vs. 4.8%; p = 0.390).
Fig. 3 Comparison of complication of cancer surgery patient in coronavirus disease 2019
(COVID-19) versus non-COVID-19 pandemic.
Preoperative COVID-19 testing was done in 68.24% of the group A and all were negative.
However, 31.76% never underwent testing. Therefore, we did a subgroup analysis in
group A for those patients undergoing COVID-19 testing versus those who did not undergo
testing. There was no significant difference in intraoperative events, blood loss,
and duration of surgery in this subgroup analysis. We also did not find any significant
difference in any parameters of postoperative complication including infection, change
of antibiotics, culture growth, and complication rates in term of CD classification.
No health-care worker was infected in direct association with surgery or postoperative
care.
Discussion
COVID-19 disease has intensely stretched the health-care system to a breakpoint. With
more than 700,000 COVID-19 cases by end-June 2020, India ranks fourth in the total
number of COVID-19 infection across the world.[8 ] Though our death rates (10 per million population) have been below the global rates
(59.6 per million population), we still are away from our peak incidence of infection.[8 ] Globally, it has been estimated that 90,000 health workers were infected till mid-May
2020.[9 ] Both our frontline workers and hospital system are already overwhelmed with COVID-19-positive
patients and treatment of non-COVID-19 disease has taken a serious toll. We do not
have sufficient studies to indicate the outcome of delays in cancer surgeries. Approximately
2,100 Indians die every day due to cancer.[10 ] These numbers would certainly increase due to straining of already resource constraints
system and synergistic effects of COVID-19 infection. Restrictive measures like national
lock down and home quarantine measures have certainly helped in taming the infection
and flattening the curve. But it had its own side effects on the health-care system
including the difficulty faced by the patients to reach hospital and additional health-care
workers being allocated to manage the COVID-19 burden.
Therefore, we decided to assess whether COVID-19 infection and the change in the way
of management of cancer patients in resource constraint settings would have any effects
on treatment and postoperative complication of cancer patients. Three-hundred sixteen
cancer patients were operated at five different tertiary care centers situated in
different parts of India. One-hundred forty-eight cancer patients were operated during
COVID-19 (2 months) as compared with 168 patients during non-COVID-19 period (1 month).
A study led by Lei et al published in April 2020 found a higher mortality rate of
20.6% in asymptomatic COVID-19-positive patients who were in their incubation period
during surgery.[11 ] Another study that analyzed 1,128 patients showed mortality rate of 23.9% during
COVID-19 period; however, it should be noted that preoperative positive severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoing elective surgeries had
lower mortality rate (9.1%) as compared with those patients who were infected in perioperative
settings (50%).[12 ] With evolving evidence against elective surgeries and all the global guidelines
favoring only emergency surgeries, 62% lesser cancer surgeries were performed in the
COVID-19 period as compared with the specific pre-COVID-19 period. It had been estimated
that there would be 72.3% cancellation of surgery world over during 12-week lockdown
period with total cancellation of surgeries accounting to 28 million procedures.[13 ] However, a study led by Shrikhande et al demonstrated no mortalities in cancer patients
operated during COVID-19 period at a tertiary care center in Mumbai. In this study,
only 23.7% were tested preoperatively for COVID-19.[6 ] Similarly, we also had 41 cancer patients operated, who were not tested for COVID-19.
In our study, we also did not encounter any mortality during the COVID-19 period.
All patients were screened for symptoms of COVID-19 in their follow-up consultation.
Time period of our study was seeing the surge in COVID-19 cases where one of the centers
was located (Mumbai). In such situation as well, we had 31.6% cases who were not tested
for COVID-19. However, we did not have any COVID-19-positive patient even in the postoperative
period. While majority of the centers participating in the study had dedicated COVID-19
wards and non-COVID-19 ICUs in their institute, results show that they were successful
in managing the COVID-19 burden without inflicting hospital-acquired COVID-19 infection
to the admitted non-COVID-19 patients. Age group operated during COVID-19 was similar
to pre-COVID-19 period. Even in COVID-19 pandemic, approximately more than half of
the surgeries were grade 3 and grade 4, which were proportionately more than pre-COVID-19.
Therefore, technically challenging surgeries did not take a backseat even during these
testing times.
Site-wise distribution of cancer surgeries represents the chronological incidence
of cancer in India. Breast cancer surgeries were the most common operative procedures.
Females outnumbered males in the number of operative procedures in COVID-19 pandemic.
Comorbidities are highly associated with high mortality rate in SARS-CoV-2-infected
patients and especially those undergoing surgeries.[14 ] In our study, more than half of the patients undergoing cancer surgeries had presence
of one or more comorbidities that was similar for both the groups. Intraoperative
parameters like intraoperative complications were similar in both the groups. However,
duration of surgery during COVID-19 period was much shorter. This could be attributed
to careful case selection during this period or less minimal invasive surgeries as
these surgeries do take a little more time as compared with open surgeries. Due to
global guidelines against the use of laparoscopic instrumentation and use of robot
during pandemic, there was significantly less usage of such minimal invasive technique.[15 ]
According to the need of the hour, we expected the surgeons to operate those patients
who would not require postoperative ICU care. However, hospital infrastructure was
equipped enough to handle such situations. We did not find any significant difference
in postoperative ICU admissions as compared with non-COVID-19 period. Postoperative
parameters including infection rate, blood culture growth, and change of antibiotics
were individually similar in both the groups. However, complication rate (CD classification)
was higher in COVID-19 period. When subgroup analysis of CD classification was done,
there was significant difference in CD-2, while all other types had a similar outcome.
This could be attributed to higher change in pharmacological management due to cumulative
higher infection rate, usage of higher antibiotics, and fever in postoperative period.
However, all patients were discharged uneventfully except one patient. One patient
took discharge against the medical advice on the fourth day. Average length of stay
was similar for both the groups. Data collected for the first two follow-ups after
the surgery showed no COVID-19-related symptoms. These two follow-up visits were within
the first 15 days after surgery in most of the patients. No patient underwent COVID-19
testing in postoperative phase. Thus, follow-up data concluded that there was no hospital
acquired infection in the study group. No health-care worker directly involved in
the patient care in the study group tested positive for COVID-19 in the stipulated
time period.
Novelty
This study is a unique collaborative work of five centers situated in different parts
of India and thus results of this study are representative of the impact of COVID-19
on cancer surgeries in hospitals across India. This is the first study to compare
perioperative morbidity in COVID-19 pandemic compared with its own dataset of non-COVID-19
pandemic thus significantly reducing the influence of confounding factors.
Limitation
It involves all the potential biases included in a retrospective review. Results are
not applicable to laboratory-confirmed COVID-19-positive cancer patients. Different
parts of India were having surges of COVID-19 infection at variable times; however,
multicentric nature of the study truly depicts the true status of major urban cities.
Implication
Hospital administration should have strategies in place to commence routine cancer
surgeries in near future with the environment that remains exposed to SARS-CoV-2.
This will help reduce the in-hospital transmission of SARS-Cov-2 without escalating
to more postoperative complications. Therefore, consideration should be given on development
of guidelines to avoid delaying or cancelling the operative procedures related to
cancer surgeries even during the pandemic.
Conclusion
Non-COVID-19 cancers patients should be treated with the same vigor as they are associated
with high mortality rate if left untreated. Our study shows that with proper planning,
training of the personnel and dedicated COVID-19 and non-COVID-19 staff, and usage
of the stipulated personal protective equipment (PPE) kits, it is possible to treat
the non-COVID-19 diseases without any significant increase in postoperative complication
rates.
